Hubert de Verneuil Selected Research

Erythropoietic Porphyria (Congenital Erythropoietic Porphyria)

12/2019	Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria).
1/2018	Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria.
1/2017	Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
11/2013	Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
7/2012	Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.
8/2011	ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
8/2010	Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation.
6/2008	Erythropoietic porphyrias: animal models and update in gene-based therapies.
6/2008	[Successful gene therapy of mice with congenital erythropoietic porphyria].
1/2008	Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hubert de Verneuil Research Topics

Disease

11	Erythropoietic Porphyria (Congenital Erythropoietic Porphyria) 12/2019 - 02/2005
7	Neoplasms (Cancer) 01/2017 - 03/2005
4	Hemolytic Anemia 12/2019 - 07/2012
4	Hypoxia (Hypoxemia) 11/2013 - 06/2007
3	Erythropoietic Protoporphyria 04/2014 - 09/2003
3	Porphyrias (Porphyria) 08/2011 - 06/2008
2	Adenocarcinoma 01/2017 - 10/2012
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 10/2012
2	Inflammation (Inflammations) 12/2011 - 09/2011
2	Genomic Instability 06/2011 - 01/2011
1	Hemolysis 12/2019
1	Congenital Hemolytic Anemia (Hemolytic Anemia, Congenital) 12/2019
1	Iron Overload 12/2019
1	Anemia 12/2019
1	Teratoma (Teratoid Tumor) 01/2017
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2013
1	Atrophy 12/2011
1	Xeroderma Pigmentosum (Kaposi's Disease) 06/2011
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2011
1	Skin Neoplasms (Skin Cancer) 01/2011
1	Liver Failure 06/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2007
1	Iron Deficiencies 01/2007
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 01/2007
1	Hypochromic Anemia (Chlorosis) 01/2007
1	Atopic Dermatitis (Atopic Eczema) 01/2007
1	Infections 01/2007
1	Asthma (Bronchial Asthma) 01/2007
1	Ichthyosis Vulgaris (Dominant Ichthyosis Vulgaris) 01/2007
1	Melanoma (Melanoma, Malignant) 03/2005
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 03/2003

Drug/Important Bio-Agent (IBA)

9	Heme (Haem)IBA 01/2018 - 09/2003
8	Uroporphyrinogen III Synthetase (Uroporphyrinogen-III Synthase)IBA 01/2018 - 01/2008
8	EnzymesIBA 01/2018 - 09/2003
5	PorphyrinsIBA 12/2019 - 06/2008
4	Proteins (Proteins, Gene)FDA Link 10/2012 - 01/2007
3	Proteasome InhibitorsIBA 01/2017 - 04/2007
3	Ferrochelatase (Heme Synthetase)IBA 04/2014 - 09/2003
3	Oxygen (Dioxygen)IBA 11/2013 - 06/2007
2	IronIBA 12/2019 - 01/2007
2	Tyrosine Kinase InhibitorsIBA 07/2013 - 01/2013
2	Transcription Factors (Transcription Factor)IBA 09/2011 - 06/2007
2	Messenger RNA (mRNA)IBA 01/2010 - 01/2007
2	protoporphyrin IXIBA 01/2007 - 09/2003
1	HepcidinsIBA 12/2019
1	Pharmaceutical PreparationsIBA 01/2018
1	Ciclopirox (Loprox)FDA LinkGeneric 01/2018
1	sulforaphaneIBA 01/2017
1	3,3',4,5'-tetrahydroxystilbeneIBA 01/2017
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017
1	Gemcitabine FDA Link 01/2017
1	Capsaicin (Zostrix)FDA Link 01/2017
1	LuciferasesIBA 01/2017
1	ResveratrolIBA 01/2017
1	SurvivinIBA 01/2017
1	Antisense OligonucleotidesIBA 04/2014
1	Surface Antigens (Surface Antigen)IBA 10/2012
1	Mucin-4IBA 10/2012
1	Ganciclovir (Cytovene)FDA LinkGeneric 10/2012
1	IntegrinsIBA 12/2011
1	5-Aminolevulinate SynthetaseIBA 08/2011
1	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2011
1	Mitochondrial DNA (mtDNA)IBA 01/2011
1	DNA Repair EnzymesIBA 01/2010
1	Transferrin (beta 2 Transferrin)IBA 01/2007
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2007
1	Immunoglobulin E (IgE)IBA 01/2007
1	Alkylating AgentsIBA 01/2007
1	Filaggrin ProteinsIBA 01/2007
1	Phosphoglycerate Kinase (Kinase, Phosphoglycerate)IBA 01/2007
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 03/2005
1	Membrane Proteins (Integral Membrane Proteins)IBA 03/2003
1	Complementary DNA (cDNA)IBA 03/2003

Therapy/Procedure

8	Therapeutics 01/2017 - 02/2005
2	Drug Therapy (Chemotherapy) 01/2017 - 04/2007
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/2008 - 02/2005
1	Subcutaneous Injections 01/2011
1	Liver Transplantation 06/2008
1	Stem Cell Transplantation 02/2005